7 New Drugs for Primary Care: Q2 2019
The end of another quarter means a new list of FDA-approved drugs for primary care. Which ones should you know about? Click through to find out.
At the close of the second quarter, Patient Care has compiled a list of 7 new FDA-approved drugs for conditions that are often seen in primary care. Below you will find details on the first generic version of Narcan®--naloxone hydrochloride nasal spray for opioid overdose; the first and only topical lotion that combines halobetasol propionate and tazarotene for the treatment of plaque psoriasis; plus 5 more.
Opioid Overdose: Naloxone Hydrochloride Nasal Spray, 4mg, (Narcan® Nasal Spray generic), is the first FDA-approved generic naloxone hydrochloride nasal spray that is designed for use by people without medical training to stop or reverse the effects of an opioid overdose. (Approved 4/19/19, Teva Pharmaceuticals, Inc.)
For full prescribing information, please click here.
Type 2 Diabetes Mellitus (T2DM): Qternmet XR (dapagliflozin, metformin hydrochloride, and saxagliptin) Extended-Release Tablets, a SGLT-2 inhibitor (dapagliflozin), DPP-4 inhibitor (saxagliptin), and biguanide (metformin hydrochloride) combination indicated for once-daily use along with diet and exercise to improve glycemic control in patients with T2DM. (Approved 5/2/19, AstraZeneca)
For full prescribing information, please click here.
Plaque Psoriasis: Duobrii (halobetasol propionate and tazarotene) Lotion, is the first and only topical lotion that combines halobetasol propionate (0.01%) and tazarotene (0.045%) for the treatment of plaque psoriasis in adults. (Approved 4/25/19, Ortho Dermatologics)
For full prescribing information, please click here.
Inflammatory Diseases: Eticovo (etanercept-ykro) Injection, is a tumor necrosis factor blocker, biosimilar to Enbrel (etanercept), approved for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis in patients aged ≥4 years, polyarticular juvenile idiopathic arthritis in patients aged ≥2 years, and psoriatic arthritis. (Approved 4/25/19, Samsung Bioepis Co., Ltd.)
For full prescribing information, please click here.
Obesity: Plenity (cellulose and citric acid) Capsules, are non-systemic, superabsorbent hydrogel capsules that increase the volume and elasticity of the stomach and small intestine to mimic the feeling the fullness. Plenity is used in conjunction with diet and exercise in adults with a body mass index of 25-40 kg/m2 to aid in weight management; launch planned for second half of 2019 and will be available by prescription in the US in 2020. (Approved 4/12/19, Gelesis)
For instructions for use, please click here.
Osteoporosis: Evenity (romosozumab-aqqg) Injection, is an anti-sclerostin monoclonal antibody injected monthly by a healthcare professional for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. One dose consists of 2 injections, one given immediately after the other, to increase new bone formation. (Approved 4/9/19, Amgen Inc.)
For full prescribing information, please click here.
Pregnancy Prevention: Slynd (drospirenone) Tablets, 4mg, the first and only progestin-only contraceptive that contains 24 active pills and 4 inactive pills with a 24-hour missed or delayed pill window for pregnancy prevention. (Approved 5/23/19, Exeltis)
For full prescribing information, please click here.
For a quick review of primary care drugs approved in the first quarter of 2019, please go to 10 New Drugs for Primary Care: Q1 2019
